Innoviva, Inc. (INVA)
21.06
+0.29
(+1.40%)
USD |
NASDAQ |
Sep 01, 10:09
Innoviva Cash from Operations (TTM) : 191.49M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 191.49M |
| March 31, 2026 | 183.60M |
| December 31, 2025 | 196.93M |
| September 30, 2025 | 201.66M |
| June 30, 2025 | 200.62M |
| March 31, 2025 | 200.26M |
| December 31, 2024 | 188.69M |
| September 30, 2024 | 162.71M |
| June 30, 2024 | 157.96M |
| March 31, 2024 | 152.43M |
| December 31, 2023 | 141.06M |
| September 30, 2023 | 116.71M |
| June 30, 2023 | 88.46M |
| March 31, 2023 | 129.31M |
| December 31, 2022 | 201.73M |
| September 30, 2022 | 291.21M |
| June 30, 2022 | 372.23M |
| March 31, 2022 | 377.81M |
| December 31, 2021 | 363.81M |
| September 30, 2021 | 350.71M |
| June 30, 2021 | 328.56M |
| March 31, 2021 | 323.74M |
| December 31, 2020 | 313.11M |
| September 30, 2020 | 294.74M |
| June 30, 2020 | 277.58M |
| Date | Value |
|---|---|
| March 31, 2020 | 254.28M |
| December 31, 2019 | 257.46M |
| September 30, 2019 | 252.33M |
| June 30, 2019 | 255.04M |
| March 31, 2019 | 250.27M |
| December 31, 2018 | 223.53M |
| September 30, 2018 | 209.61M |
| June 30, 2018 | 192.99M |
| March 31, 2018 | 163.90M |
| December 31, 2017 | 141.75M |
| September 30, 2017 | 114.98M |
| June 30, 2017 | 91.67M |
| March 31, 2017 | 81.50M |
| December 31, 2016 | 60.98M |
| September 30, 2016 | 46.82M |
| June 30, 2016 | 29.28M |
| March 31, 2016 | 19.00M |
| December 31, 2015 | 10.13M |
| September 30, 2015 | -1.396M |
| June 30, 2015 | -25.12M |
| March 31, 2015 | -81.70M |
| December 31, 2014 | -130.72M |
| September 30, 2014 | -166.09M |
| June 30, 2014 | -186.33M |
| March 31, 2014 | -148.61M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Zevra Therapeutics, Inc. | 33.40M |
| Collegium Pharmaceutical, Inc. | 329.92M |
| CorMedix, Inc. | 253.62M |
| ANI Pharmaceuticals, Inc. | 189.47M |
| Corcept Therapeutics, Inc. | 109.70M |